Literature DB >> 29171929

AHNS Series: Do you know your guidelines? Principles of treatment for locally advanced or unresectable head and neck squamous cell carcinoma.

Cory D Fulcher1, Missak Haigentz2,3,4, Thomas J Ow5.   

Abstract

This article is a continuation of the "Do You Know Your Guidelines" series, initiated by the Education committee of the American Head and Neck Society. Treatment guidelines for advanced head and neck squamous cell carcinoma are reviewed here, including the critical roles of radiotherapy, chemotherapy, and the recent application of immunotherapy agents. We will be limiting this discussion to include cancers of the oral cavity, oropharynx, hypopharynx, and larynx. It should be noted that much of the article pertains to human papillomavirus (HPV)-negative oropharyngeal cancer where applicable, as HPV-positive oropharyngeal squamous cell carcinoma carries a different natural history, different prognosis, and now different staging criteria. Additionally, the article will not include information on nasopharyngeal or sinus cancers, as these latter topics are covered in separate "Do you know your guidelines?" installments and these diagnoses carry somewhat different approaches to diagnosis and management that diverge from the focus of this article.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  National Comprehensive Cancer Network; advanced head and neck cancer; guidelines as topic; head and neck cancer; management

Mesh:

Year:  2017        PMID: 29171929      PMCID: PMC5849482          DOI: 10.1002/hed.25025

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  106 in total

1.  Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer.

Authors:  J P Pignon; J Bourhis; C Domenge; L Designé
Journal:  Lancet       Date:  2000-03-18       Impact factor: 79.321

Review 2.  Prognostic indicators in head and neck oncology including the new 7th edition of the AJCC staging system.

Authors:  Margaret Brandwein-Gensler; Richard V Smith
Journal:  Head Neck Pathol       Date:  2010-02-06

Review 3.  Afatinib in squamous cell carcinoma of the head and neck.

Authors:  Pol Specenier; Jan Vermorken
Journal:  Expert Opin Pharmacother       Date:  2016-05-19       Impact factor: 3.889

Review 4.  Second primary tumors in patients with head and neck cancer.

Authors:  Antonio Vitor Martins Priante; Emanuel Celice Castilho; Luiz Paulo Kowalski
Journal:  Curr Oncol Rep       Date:  2011-04       Impact factor: 5.075

5.  Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.

Authors:  Robert Haddad; Anne O'Neill; Guilherme Rabinowits; Roy Tishler; Fadlo Khuri; Douglas Adkins; Joseph Clark; Nicholas Sarlis; Jochen Lorch; Jonathan J Beitler; Sewanti Limaye; Sarah Riley; Marshall Posner
Journal:  Lancet Oncol       Date:  2013-02-13       Impact factor: 41.316

Review 6.  Distant metastases from head and neck squamous cell carcinoma. Part III. Treatment.

Authors:  Missak Haigentz; Dana M Hartl; Carl E Silver; Johannes A Langendijk; Primož Strojan; Vinidh Paleri; Remco de Bree; Jean-Pascal Machiels; Marc Hamoir; Alessandra Rinaldo; Daniela Paccagnella; Ashok R Shaha; Robert P Takes; Alfio Ferlito
Journal:  Oral Oncol       Date:  2012-04-18       Impact factor: 5.337

7.  Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck.

Authors:  M Merlano; M Benasso; R Corvò; R Rosso; V Vitale; F Blengio; G Numico; G Margarino; L Bonelli; L Santi
Journal:  J Natl Cancer Inst       Date:  1996-05-01       Impact factor: 13.506

8.  B7-H1 expression model for immune evasion in human papillomavirus-related oropharyngeal squamous cell carcinoma.

Authors:  Odey C Ukpo; Wade L Thorstad; James S Lewis
Journal:  Head Neck Pathol       Date:  2012-11-20

9.  Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.

Authors:  D M Brizel; M E Albers; S R Fisher; R L Scher; W J Richtsmeier; V Hars; S L George; A T Huang; L R Prosnitz
Journal:  N Engl J Med       Date:  1998-06-18       Impact factor: 91.245

10.  Cetuximab: its unique place in head and neck cancer treatment.

Authors:  Pol Specenier; Jan B Vermorken
Journal:  Biologics       Date:  2013-04-15
View more
  7 in total

Review 1.  The Rationale for "Laser-Induced Thermal Therapy (LITT) and Intratumoral Cisplatin" Approach for Cancer Treatment.

Authors:  Renan Vieira de Brito; Marília Wellichan Mancini; Marcel das Neves Palumbo; Luis Henrique Oliveira de Moraes; Gerson Jhonatan Rodrigues; Onivaldo Cervantes; Joel Avram Sercarz; Marcos Bandiera Paiva
Journal:  Int J Mol Sci       Date:  2022-05-25       Impact factor: 6.208

2.  M2 macrophages reduce the radiosensitivity of head and neck cancer by releasing HB‑EGF.

Authors:  Enhui Fu; Tianyang Liu; Siyang Yu; Xiaohang Chen; Lianhao Song; Huihuang Lou; Fen Ma; Siwei Zhang; Sajjad Hussain; Junnan Guo; Ji Sun; Pingyang Yu; Xionghui Mao; Lanlan Wei
Journal:  Oncol Rep       Date:  2020-05-29       Impact factor: 3.906

3.  Predictive factors of toxicity of TPF induction chemotherapy for locally advanced head and neck cancers.

Authors:  Maureen Bernadach; Michel Lapeyre; Anne-Françoise Dillies; Jessica Miroir; Melanie Casile; Juliette Moreau; Ioana Molnar; Angeline Ginzac; Nathalie Pham-Dang; Nicolas Saroul; Xavier Durando; Julian Biau
Journal:  BMC Cancer       Date:  2021-04-07       Impact factor: 4.430

4.  Laryngeal Squamous Cell Carcinoma: Potential Molecular Mechanism and Prognostic Signature Based on Immune-Related Genes.

Authors:  Bin-Yu Mo; Guo-Sheng Li; Su-Ning Huang; Zhu-Xin Wei; Ya-Si Su; Wen-Bin Dai; Lin Ruan
Journal:  Med Sci Monit       Date:  2020-12-26

Review 5.  The Epithelial-Mesenchymal Transition Influences the Resistance of Oral Squamous Cell Carcinoma to Monoclonal Antibodies via Its Effect on Energy Homeostasis and the Tumor Microenvironment.

Authors:  Yunpeng Bai; Jingjing Sha; Tatsuo Okui; Ichiro Moriyama; Huy Xuan Ngo; Hiroto Tatsumi; Takahiro Kanno
Journal:  Cancers (Basel)       Date:  2021-11-24       Impact factor: 6.639

6.  Methotrexate and Cetuximab-Biological Impact on Non-Tumorigenic Models: In Vitro and In Ovo Assessments.

Authors:  Andreea M Kis; Ioana Macasoi; Corina Paul; Matilda Radulescu; Roxana Buzatu; Claudia G Watz; Adelina Cheveresan; Delia Berceanu; Iulia Pinzaru; Stefania Dinu; Aniko Manea; Marioara Poenaru; Claudia Borza; Cristina A Dehelean
Journal:  Medicina (Kaunas)       Date:  2022-01-22       Impact factor: 2.430

7.  Real-World Outcomes and Prognostic Factors in Patients Receiving Nivolumab Therapy for Recurrent or Metastatic Head and Neck Carcinoma.

Authors:  Ryusuke Hori; Shogo Shinohara; Tsuyoshi Kojima; Hiroki Kagoshima; Morimasa Kitamura; Ichiro Tateya; Hisanobu Tamaki; Yohei Kumabe; Ryo Asato; Hiroyuki Harada; Yoshiharu Kitani; Takashi Tsujimura; Keigo Honda; Kazuyuki Ichimaru; Koichi Omori
Journal:  Cancers (Basel)       Date:  2019-09-06       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.